Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Pharmaceuticals Secures Funding into 2028, Reports Q4 Loss, and Updates Positive Clinical Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$8.01
Mkt Cap
$140.6M
52W Low
$4.64
52W High
$20.56
52W Position info
73% above low
Off High info
61% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CRBP sits 73% above its 52-week low of $4.64.

Summary

Corbus Pharmaceuticals reported a wider net loss for Q4 and full year 2025 but significantly extended its cash runway into 2028 following a $75 million public offering. The company also provided positive clinical updates for its oncology and obesity programs, CRB-701 and CRB-913.


Key Events · Financing and Capital Events · CRBP

  • Extended Cash Runway

    The company secured $163.3 million in cash, cash equivalents, and investments as of December 31, 2025, following a $75 million public offering in Q4 2025, extending its operational runway into 2028.

  • Wider Net Loss Reported

    Corbus Pharmaceuticals reported a net loss of $20.6 million ($1.25 per share) for Q4 2025 and $78.5 million ($5.90 per share) for the full year 2025, a significant increase from the prior year.

  • Positive Clinical Data for CRB-701

    The company presented encouraging Phase 1/2 data for its Nectin-4 ADC, CRB-701, in HNSCC and cervical cancer, showing promising objective response rates and favorable safety.

  • Encouraging CRB-913 Obesity Data

    A Phase 1a study for its oral CB1 inverse agonist, CRB-913, was completed, demonstrating 2.9% placebo-adjusted weight loss at 14 days with a favorable GI safety profile.


Analysis · CRBP · Life Sciences

This 8-K filing provides a comprehensive update on Corbus Pharmaceuticals' financial health and pipeline progress. While the company reported a significantly wider net loss for Q4 and full year 2025, the successful completion of a $75 million public offering in Q4 2025 is a critical development, extending the cash runway into 2028. This substantial capital raise provides crucial financial stability for a clinical-stage biotech, mitigating near-term liquidity concerns. Furthermore, the company presented encouraging clinical data for its lead oncology asset, CRB-701, in HNSCC and cervical cancer, and positive early data for its obesity drug, CRB-913. The strategic decision to deprioritize less promising programs (CRB-601 and CRB-701's mUC indication) allows for a more focused allocation of resources towards these key assets, which have upcoming catalysts in 2026. Investors should monitor the progress of CRB-701 and CRB-913 as they advance through clinical development, supported by the company's extended financial runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBP was trading at $8.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $140.6M. The 52-week trading range was $4.64 to $20.56. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBP - Latest Insights

CRBP
Nov 16, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.18 info
Change: -$0.2725 (-8%) info
Market Cap: $65.117M info
CRBP
Nov 10, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $3.18 info
Change: -$0.345 (-10%) info
Market Cap: $65.117M info
CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $3.18 info
Change: -$3.91 (-55%) info
Market Cap: $65.117M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $3.18 info
Change: -$6.09 (-66%) info
Market Cap: $65.117M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $3.18 info
Change: -$5.74 (-64%) info
Market Cap: $65.117M info